CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
27
2
4
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 27 trials
100.0%
+13.5% vs industry average
44%
12 trials in Phase 3/4
0%
0 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects
Role: lead
A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma
Role: lead
A Study of TG103 Injection Monotherapy in Treatment of Type 2 Diabetes Mellitus
Role: lead
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM326 in Participants With Chronic Rhinosinusitis With Nasal Polyposis
Role: lead
A Study of TG103 Injection in Non-diabetic Overweight or Obesity
Role: lead
A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus
Role: lead
A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity
Role: lead
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
Role: lead
Semaglutide in Treatment of Obesity
Role: lead
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem Cells
Role: collaborator
A Study of TG103 Injection in Overweight/Obese Subjects Without Diabetes
Role: lead
A Study of TG103 Injection in Type 2 Diabetes Subjects
Role: lead
A Study of TG103 Injection in Overweight or Obesity
Role: lead
A Comparative Study of TG103 Produced by Two Manufacturing Processes in Chinese Healthy Male Subjects
Role: lead
A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes
Role: lead
Study to Evaluate the Therapeutic Equivalence of SYN008 Versus Xolair® in the Treatment of Patients With Refractory Chronic Spontaneous Urticaria
Role: lead
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
Role: lead
Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies
Role: lead
Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma
Role: lead
Efficacy and Safety of Pegylated Recombinant Human Granulocyte Stimulating Factor in Secondary Prevention of Albumin Paclitaxel Combined With S-1 in the First-line Treatment of Advanced Pancreatic Cancer
Role: lead